Trial of Metformin for Colorectal Cancer Risk Reduction for History of Colorectal Adenomas and Elevated BMI
Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out whether METFORMIN decreases protein markers in
colorectal tissue. This is a phase IIA study of the pharmacodynamics, safety and tolerability
of Metformin in decreasing colorectal mucosa in patients with a history of colorectal
adenomas in the past 3 years and a BMI >= 30, with decimals rounded to the nearest whole
integer. Metformin as a potential chemopreventive agent for inhibition of the relevant
molecular pathways involved in human colorectal carcinogenesis.